Global POC Diagnostics Market Outlook, 2031

The global point-of-care diagnostics landscape has shifted markedly as healthcare systems push for rapid, decentralized testing that brings results closer to patients rather than relying on centralized laboratories. This evolution has been shaped by the need for faster clinical decision-making, particularly in emergency care, infectious disease screening, and chronic disease monitoring. The COVID-19 pandemic acted as a major catalyst, accelerating adoption of rapid molecular and antigen testing technologies and normalizing home-based and near-patient diagnostics. Companies such as Abbott Laboratories with its ID NOW platform and F. Hoffmann-La Roche AG through its cobas Liat system have played a central role in delivering compact molecular testing solutions capable of delivering results within minutes. At the same time, regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency have adapted approval pathways to accommodate faster diagnostic innovations, further supporting market momentum. Technological convergence has also been evident as digital health integration, including connectivity to cloud platforms and mobile applications, has allowed devices to transmit patient results in real time to clinicians, strengthening telemedicine ecosystems. Organizations such as Siemens Healthineers and Becton, Dickinson and Company have expanded their point-of-care portfolios to include multiplex testing and portable analyzers that address multiple disease markers simultaneously. The growing burden of diseases such as diabetes, cardiovascular conditions, and infectious outbreaks across both developed and emerging economies has further reinforced the need for rapid diagnostics outside traditional lab settings. Additionally, initiatives supported by entities like the World Health Organization and national health ministries are encouraging deployment of diagnostic tools in rural and resource-limited regions, helping bridge gaps in healthcare accessibility and strengthening early detection capabilities across the global healthcare continuum.

The market’s current trajectory is marked by a strong emphasis on innovation, with manufacturers investing heavily in miniaturization, biosensor technologies, and lab-on-a-chip systems that allow complex assays to be performed with minimal infrastructure. The expansion of immunoassay-based rapid testing and molecular amplification techniques has enabled more accurate and reliable detection at the point of care, reducing dependency on centralized laboratory workflows. Companies such as Danaher Corporation through its subsidiaries like Cepheid have introduced cartridge-based molecular platforms that automate sample preparation and analysis, significantly reducing human error. Strategic collaborations have also become a defining feature, with partnerships between diagnostic firms and digital health providers enabling integrated platforms that combine diagnostics with data analytics. The rise of decentralized healthcare models, especially in home care and outpatient settings, has been reinforced by wearable-compatible diagnostic devices and smartphone-linked test kits developed by companies like Siemens Healthineers and Abbott Laboratories. In parallel, investments from organizations such as the Bill & Melinda Gates Foundation have supported the deployment of affordable diagnostic tools in low-income regions, particularly for infectious diseases like HIV, tuberculosis, and malaria. Regulatory advancements, including streamlined approval processes for in vitro diagnostics in regions like the United States and Europe, have further accelerated product commercialization. At the same time, increasing demand from hospitals, urgent care centers, and even pharmacies has broadened the application scope of point-of-care testing, reinforcing its role as a critical component of modern healthcare delivery systems worldwide.

Market Dynamics

Market Drivers

• Rapid Decentralized Testing: Expansion of decentralized healthcare delivery is driving strong adoption of point-of-care diagnostics as it reduces dependency on centralized laboratories and accelerates clinical decisions. Devices like Abbott ID NOW and Cepheid GeneXpert enable molecular results within minutes, supporting emergency care and infectious disease control. Growing use in clinics, pharmacies, and home settings, along with support from organizations like the World Health Organization, has further strengthened demand for fast, near-patient diagnostic solutions globally.
• Rising Chronic Disease Burden: Increasing prevalence of chronic conditions such as diabetes and cardiovascular disorders is fueling continuous demand for real-time monitoring and frequent testing. Roche Diagnostics has expanded glucose monitoring and cardiac testing solutions that allow patients and clinicians to track health parameters instantly. Aging populations and lifestyle-related diseases, especially in regions like North America and Asia-Pacific, are intensifying the need for convenient diagnostic tools that support long-term disease management outside traditional laboratory settings.



Market Challenges

• Regulatory Complexity Barriers: Stringent regulatory frameworks across regions create significant hurdles for rapid commercialization of point-of-care diagnostic products. Agencies like the U.S. Food and Drug Administration and European Medicines Agency require extensive validation for accuracy and reliability, particularly for molecular diagnostics. Companies such as Siemens Healthineers and Abbott Laboratories must navigate complex approval pathways, which can delay product launches and increase development costs, limiting faster innovation diffusion in emerging markets.
• High Device Costs: Advanced point-of-care diagnostic systems often involve high upfront investment and maintenance expenses, limiting adoption in resource-constrained settings. Technologies developed by Danaher Corporation and Becton, Dickinson and Company require specialized consumables and training, increasing overall operational costs. In low- and middle-income countries, budget constraints and lack of reimbursement frameworks further restrict widespread deployment, making affordability a major barrier to scaling these technologies globally.

Market Trends

• Digital Health Integration: Integration of diagnostics with digital platforms is transforming the point-of-care landscape by enabling real-time data sharing and remote patient monitoring. Devices from F. Hoffmann-La Roche AG and Abbott Laboratories are increasingly connected to cloud-based systems, allowing clinicians to access results instantly and integrate them into electronic health records. This trend supports telemedicine growth and enhances clinical decision-making, particularly in remote and underserved regions where access to healthcare professionals is limited.
• Multiplex Testing Growth: The demand for multiplex diagnostic platforms capable of detecting multiple pathogens or biomarkers simultaneously is rising rapidly. Platforms such as Cepheid GeneXpert illustrate the shift toward comprehensive testing in a single run, reducing time and improving diagnostic accuracy. This trend is particularly relevant in infectious disease management, where co-infections are common. Companies like Danaher Corporation are investing in expanding assay menus, enabling broader clinical applications and improving efficiency in point-of-care environments.

Segment Analysis

Classification based on test type reflects the diverse clinical applications of point-of-care diagnostics across disease management, preventive screening, and emergency care, enabling faster decision-making and improved patient outcomes across healthcare settings.

The segmentation of the point-of-care diagnostics market by type reflects the broad clinical utility of rapid testing solutions across multiple disease areas, each addressing specific diagnostic needs. Blood glucose testing represents one of the most widely adopted segments, driven by the global prevalence of diabetes and the need for continuous monitoring, with devices such as Abbott FreeStyle Libre enabling real-time glucose tracking without traditional finger-prick methods. Infectious disease testing has gained prominence, especially after the COVID-19 pandemic, with platforms like Roche cobas Liat allowing rapid detection of respiratory infections and other pathogens. Cardiac marker testing, including troponin-based assays, supports emergency diagnosis of myocardial infarction, while coagulation testing is critical for monitoring patients on anticoagulant therapy using systems like Roche CoaguChek. Pregnancy and fertility testing remain high-volume applications in both clinical and home settings, supported by products from Procter & Gamble such as the Clearblue brand, which offers highly sensitive hCG detection. Blood gas and electrolyte testing is essential in critical care units, where devices from Siemens Healthineers provide rapid assessment of oxygen, carbon dioxide, and acid-base balance. Tumor marker testing is gaining traction for early cancer detection and monitoring, with advancements from companies like F. Hoffmann-La Roche AG. Urinalysis testing is widely used for detecting urinary tract infections and kidney disorders, while cholesterol testing supports cardiovascular risk assessment and preventive care. Other applications include drug-of-abuse testing and infectious disease screening for conditions like HIV and malaria, reflecting the expanding scope of decentralized diagnostics across global healthcare systems.

Segmentation by application highlights how point-of-care diagnostics are integrated into different healthcare delivery environments, each with unique workflow requirements, patient volumes, and access to laboratory infrastructure.

The application of point-of-care diagnostics in medicine spans across multiple healthcare settings, each benefiting from rapid and accurate testing capabilities. Clinics represent a major application area where physicians rely on compact diagnostic devices for quick decision-making during patient consultations, improving workflow efficiency and reducing patient wait times. Hospitals remain a dominant segment due to high patient inflow and critical care requirements, where point-of-care systems are extensively used in emergency departments, intensive care units, and operating rooms to provide immediate test results that guide urgent treatment decisions. Laboratory settings, while traditionally associated with centralized testing, are increasingly adopting near-patient diagnostics to complement high-throughput systems and reduce turnaround times, with companies like Danaher Corporation offering integrated diagnostic solutions. The “others” category includes home care settings, ambulatory surgical centers, and pharmacies, where self-testing and pharmacist-led diagnostics are becoming more common, supported by innovations from Abbott Laboratories and Roche Diagnostics. The expansion of telemedicine and remote patient monitoring has further strengthened the role of point-of-care diagnostics in non-traditional settings, enabling patients to perform tests at home and share results digitally with healthcare providers. This widespread adoption across diverse applications underscores the growing importance of decentralized testing in improving healthcare accessibility, reducing diagnostic delays, and enhancing overall patient care outcomes across the global medical ecosystem.  
Regional Analysis

The medical application of point-of-care diagnostics focuses on enabling rapid, accurate, and near-patient testing across clinical settings, improving treatment outcomes, reducing diagnostic delays, and supporting real-time clinical decision-making in both routine and emergency care.

The point-of-care diagnostics market in medicine has evolved into a critical component of modern healthcare delivery by enabling rapid testing directly at or near the patient, thereby reducing dependence on centralized laboratories and improving response times in clinical decision-making. This market encompasses a wide range of diagnostic technologies used in hospitals, clinics, laboratories, and increasingly in home and remote care settings. The adoption of advanced molecular and immunoassay-based platforms has significantly enhanced the accuracy and reliability of near-patient testing, allowing clinicians to detect conditions such as infectious diseases, diabetes, cardiovascular disorders, and cancer biomarkers with greater efficiency. Devices like Abbott ID NOW and Cepheid GeneXpert have demonstrated how rapid molecular diagnostics can deliver results within minutes, which is crucial in emergency departments and intensive care units. The integration of digital connectivity in diagnostic devices has further strengthened the market, enabling seamless data transfer to electronic health records and supporting telemedicine initiatives, with companies such as Siemens Healthineers and F. Hoffmann-La Roche AG leading innovations in this area. Increasing prevalence of chronic diseases and infectious outbreaks has also driven demand for continuous monitoring and rapid screening, particularly in aging populations. Moreover, advancements in biosensor technology, microfluidics, and lab-on-a-chip systems have made it possible to perform complex analyses using compact, portable devices. Regulatory bodies such as the U.S. Food and Drug Administration and the European Medicines Agency have adapted frameworks to accelerate approval of diagnostic tools, ensuring safety while encouraging innovation. In addition, organizations like the World Health Organization are promoting access to affordable diagnostics in low-resource regions, further expanding the reach of point-of-care testing in global healthcare systems. This growing adoption across diverse medical applications underscores its vital role in enhancing patient outcomes and transforming healthcare delivery models worldwide.

Key Developments

• June 2024: bioMérieux (France) received US FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini.
• June 2024: F. Hoffmann-La Roche Ltd (Switzerland) acquired LumiraDx’s (US) Point of Care technology to further expand its offering in decentralized patient care and drive global access to timely and actionable diagnostic results.
• April 2024: Abbott’s (US) i-STAT TBI cartridge received clearance from the US FDA to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes.
• December 2023 : Thermo Fisher Scientific Inc. (US) partnered with Project HOPE, an innovative and leading global health and humanitarian organization, to improve the access to Thermo Fisher HIV testing services amongst the HIV positive youth in Sub-Saharan Africa.
• April 2023 : BIOSYNEX SA (France) acquired Chembio Diagnostics, Inc. (US) a leading point of care diagnostics company focused on infectious diseases.